Back to Search
Start Over
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.
- Source :
-
MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2018 Jan 26; Vol. 67 (3), pp. 103-108. Date of Electronic Publication: 2018 Jan 26. - Publication Year :
- 2018
-
Abstract
- On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01 <subscript>B</subscript> ), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years. The vaccine consists of 2 doses (0.5 mL each), administered intramuscularly, 2-6 months apart (1). On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years.<br />Competing Interests: No conflicts of interest were reported.
- Subjects :
- Advisory Committees
Aged
Humans
Immunization Schedule
Immunocompetence
Middle Aged
United States
United States Food and Drug Administration
Vaccines, Attenuated administration & dosage
Vaccines, Synthetic administration & dosage
Herpes Zoster prevention & control
Herpes Zoster Vaccine administration & dosage
Practice Guidelines as Topic
Subjects
Details
- Language :
- English
- ISSN :
- 1545-861X
- Volume :
- 67
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- MMWR. Morbidity and mortality weekly report
- Publication Type :
- Academic Journal
- Accession number :
- 29370152
- Full Text :
- https://doi.org/10.15585/mmwr.mm6703a5